Pricing Log in Create free account
Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

905.02 2.12 +0.23%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 6:55 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2026: 6 added · 4 removed · 30 modified; 6 with only figures updated

  1. Modified

    •risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 12 to our Condensed Consolidated Financial Statements included in this report), risks associated with intellectual property of the Company or other parties and pending or future litigation or patent office proceedings relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 12 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome

39 more changes in this Item, word by word, in Powerpack.